Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: An open-label, multicentre, single-arm, phase 2 study

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages 459-464

  Abergel, Armand ^a   Asselah, Tarik ^b,c   Metivier, Sophie ^d   Kersey, Kathryn ^e   Jiang, Deyuan ^e   Mo, Hongmei ^e   Pang, Phillip S ^e   Samuel, Didier ^f   Loustaud Ratti, Véronique ^g  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b BEAUJON HOSPITAL   (France)

^c INSERM   (France)

^d CHU PURPAN   (France)

^e GILEAD SCIENCES   (United States)

^f HÔPITAL PAUL BROUSSE   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; FATIGUE; FEMALE; FRANCE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; LIVER CIRRHOSIS; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VIRUS TYPING; AGED; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS LOAD;

ADMINISTRATION, ORAL; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84955473429     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00529-0     Document Type: Article

References (20)

1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61:77-87.
2. Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 2009, 137:79-84.
3. Antaki N, Abboud D, Antaki F, Craxi A HCV genotype 5: an orphan virus. Antivir Ther 2013, 18:263-269.
4. Legrand-Abravanel F, Sandres-Sauné K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004, 189:1397-1400.
5. Abergel A, Ughetto S, Dubost S, et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 2007, 26:1437-1446.
6. Henquell C, Guglielmini J, Verbeeck J, et al. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. Infect Genet Evol 2011, 11:496-503.
7. Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006, 24:593-600.
8. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516.
9. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
10. Devaki P, Jencks D, Yee BE, Nguyen MH Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients. Hepatol Int 2015, 9:431-437.
11. HCV guidance: recommendations for testing, managing, and treating hepatitis C American Association for the Study of Liver Diseases and Infectious Diseases Society of America, (accessed Jan 23, 2015). http://www.hcvguidelines.org/.
12. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 63:199-236. European Association for the Study of Liver.
13. Asselah T, Marcellin P Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. Liver Int 2015, 35(suppl 1):56-64.
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
15. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
16. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY Trial. Hepatology 2014, 60(suppl):321A. (abstract).
17. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroentorology 2015, 149:1454-1461.
18. Sonderup MW, Abuelhassan W, Spearman CW IL28B polymorphisms are not predictive in hepatitis C genotype 5 infected South African patients. Hepatology 2012, 56(suppl S1):1029A.
19. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012, 61:1640-1641.
20. Forns X, Gordon S, Zuckerman, et al. C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy. J Hepatol 2015, 62(suppl 2):S190.